biotech investing argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
biotech investing argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
biotech investing argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
biotech investing argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
biotech investing argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
biotech investing argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer
biotech investing argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
biotech investing argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
SAGA Metals Mobilizes Camp Construction Ahead of Drilling at Wolverine Heavy Rare Earth Element Project in Labrador
